Clinafloxacin | CAS# 105956-97-6 (free base) | fluoroquinolone antibiotic

MedKoo Cat#: 413082 | Name: Clinafloxacin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clinafloxacin is an investigational fluoroquinolone antibiotic. Despite its promising antibiotic activity, the clinical development of clinafloxacin has been hampered by its risk for inducing serious side effects.

Chemical Structure

Clinafloxacin

CAS#105956-97-6 (free base)

Theoretical Analysis

MedKoo Cat#: 413082

Name: Clinafloxacin

CAS#: 105956-97-6 (free base)

Chemical Formula: C17H17ClFN3O3

Exact Mass: 365.0942

Molecular Weight: 365.79

Elemental Analysis: C, 55.82; H, 4.68; Cl, 9.69; F, 5.19; N, 11.49; O, 13.12

Price and Availability

Size	Price	Availability
50mg	USD 385.00	2 Weeks
100mg	USD 650.00	2 Weeks
250mg	USD 1,150.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

105956-97-6 (free base) 105956-99-8 (HCl)

Synonym

Clinafloxacin; PD127321; PD-127321; PD 127321

IUPAC/Chemical Name

3-Quinolinecarboxylic acid, 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-

InChi Key

QGPKADBNRMWEQR-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H17ClFN3O3/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9/h5,7-9H,1-4,6,20H2,(H,24,25)

SMILES Code

O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CC(N)CC4)=C3Cl)C1=O)O

Appearance

Solid powder

Purity

>97% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 365.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Buglak AA, Shanin IA, Eremin SA, Lei HT, Li X, Zherdev AV, Dzantiev BB. Ciprofloxacin and Clinafloxacin Antibodies for an Immunoassay of Quinolones: Quantitative Structure⁻Activity Analysis of Cross-Reactivities. Int J Mol Sci. 2019 Jan 11;20(2):265. doi: 10.3390/ijms20020265. PMID: 30641870; PMCID: PMC6359390. 2: Matuschka PR, Vissing RS. Clinafloxacin-theophylline drug interaction. Ann Pharmacother. 1995 Apr;29(4):378-80. doi: 10.1177/106002809502900407. PMID: 7633015. 3: Randinitis EJ, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AJ. Clinafloxacin pharmacokinetics in subjects with various degrees of renal function. Antimicrob Agents Chemother. 2001 Sep;45(9):2536-42. doi: 10.1128/aac.45.9.2536-2542.2001. PMID: 11502526; PMCID: PMC90689. 4: Siami FS, LaFleur BJ, Siami GA. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center. Clin Ther. 2002 Jan;24(1):59-72. doi: 10.1016/s0149-2918(02)85005-6. PMID: 11833836. 5: Siami G, Christou N, Eiseman I, Tack KJ; Severe Skin and Soft Tissue Infections Study Group. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2001 Feb;45(2):525-31. doi: 10.1128/AAC.45.2.525-531.2001. PMID: 11158750; PMCID: PMC90322. 6: Vila J, Ribera A, Marco F, Ruiz J, Mensa J, Chaves J, Hernandez G, Jimenez De Anta MT. Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2002 Mar;49(3):471-7. doi: 10.1093/jac/49.3.471. PMID: 11864947. 7: Bode K, Kunz A, Baumann-Wilschke I, Shakibaei M, Stahlmann R. Effects of moxifloxacin and clinafloxacin on murine limb buds cultured in regular and in magnesium-deficient medium. Arch Toxicol. 2010 Mar;84(3):221-6. doi: 10.1007/s00204-009-0490-3. Epub 2009 Dec 1. PMID: 19949773. 8: Domenech A, Cabellos C, Ribes S, Tubau F, Viladrich PF, Liñares J, Gudiol F. Experimental study of clinafloxacin alone and in combination in the treatment of ciprofloxacin-susceptible and -resistant pneumococcal meningitis. Microb Drug Resist. 2003;9 Suppl 1:S53-9. doi: 10.1089/107662903322541900. PMID: 14633368. 9: Nagai K, Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2000 Oct;44(10):2740-6. doi: 10.1128/aac.44.10.2740-2746.2000. PMID: 10991854; PMCID: PMC90145. 10: Solomkin JS, Wilson SE, Christou NV, Rotstein OD, Dellinger EP, Bennion RS, Pak R, Tack K. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann Surg. 2001 Jan;233(1):79-87. doi: 10.1097/00000658-200101000-00013. PMID: 11141229; PMCID: PMC1421170.